Live feed08:00:00·931dPRReleasevia QuantisnowNeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy EndpointsByQuantisnow·Wall Street's wire, on your screen.NRSN· NeuroSense Therapeutics Ltd.Health Care
